Asset-light Indian pharma firm selling niche Gynaecology, Orthopaedics, Dermatology & Paediatric brands.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 98 | 109 | 120 | 146 | 174 | 227 | 240 | 263 |
| Borrowings | 5 | 7 | 0 | 6 | 9 | 9 | 9 | 8 |
| Other Liabilities | 31 | 35 | 31 | 30 | 21 | 29 | 37 | 32 |
| Total Liabilities | 147 | 164 | 164 | 195 | 217 | 278 | 299 | 317 |
| AssetsFixed Assets | 22 | 26 | 23 | 24 | 9 | 94 | 90 | 85 |
| CWIP | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 11 | 15 | 51 | 1 | 0 | 0 | 0 | 0 |
| Other Assets | 109 | 123 | 91 | 170 | 208 | 184 | 209 | 231 |
| Total Assets | 147 | 164 | 164 | 195 | 217 | 278 | 299 | 317 |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (38.8×) and current (32.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 17.4% growth and a 33× exit, ₹212 only delivers your return if you pay ₹212. The price is currently baking in 17% growth.
EPS grows 17.4%/yr for 5 years, then fades to 6% over 2, exits at 33×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 17.4% | 7.58 |
| FY28 | 17.4% | 8.90 |
| FY29 | 17.4% | 10.45 |
| FY30 | 17.4% | 12.27 |
| FY31 | 17.4% | 14.41 |
| FY32 | 11.7% ·fade | 16.09 |
| FY33 | 6.0% ·fade | 17.06 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.